Cullinan Therapeutics (CGEM) Files 8-K

Ticker: CGEM · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1789972

Cullinan Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyCullinan Therapeutics, Inc. (CGEM)
Form Type8-K
Filed DateJun 3, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-update, sec-filing

Related Tickers: CGEM

TL;DR

CGEM filed a routine 8-K confirming its address and Nasdaq listing.

AI Summary

Cullinan Therapeutics, Inc. (CGEM) filed an 8-K on June 01, 2024, reporting its principal executive offices at One Main Street, Suite 1350, Cambridge, Massachusetts. The filing confirms the company's common stock is traded on The Nasdaq Global Select Market under the symbol CGEM. No specific financial transactions or material events were detailed in this particular filing.

Why It Matters

This 8-K filing serves as a standard corporate update, confirming the company's registered address and stock exchange listing, which is important for regulatory compliance and investor information.

Risk Assessment

Risk Level: low — This filing is a routine administrative update and does not contain information that suggests a change in the company's risk profile.

Key Players & Entities

  • Cullinan Therapeutics, Inc. (company) — Registrant
  • CGEM (company) — Trading Symbol
  • June 01, 2024 (date) — Date of earliest event reported
  • One Main Street, Suite 1350, Cambridge, Massachusetts 02142 (address) — Principal Executive Offices
  • The Nasdaq Global Select Market (company) — Exchange

FAQ

What is the primary purpose of this 8-K filing for Cullinan Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report current information as required by the SEC, specifically confirming the company's principal executive offices and its stock trading on The Nasdaq Global Select Market.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on June 01, 2024.

What is the trading symbol for Cullinan Therapeutics, Inc. common stock?

The trading symbol for Cullinan Therapeutics, Inc. common stock is CGEM.

On which exchange is Cullinan Therapeutics, Inc. common stock registered?

Cullinan Therapeutics, Inc. common stock is registered on The Nasdaq Global Select Market.

Does this filing indicate any new financial transactions or material events for Cullinan Therapeutics?

No, this specific 8-K filing does not detail any new financial transactions or material events; it primarily serves as an update on the company's corporate information and listing.

Filing Stats: 895 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2024-06-03 08:12:14

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CGEM The Nasdaq

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 1, 2024, Cullinan Therapeutics, Inc. (the "Company") issued a press release related to the announcement of initial clinical data from the pivotal Phase 2b portion of its REZILIENT1 clinical trial of zipalertinib in patients with non-small cell lung cancer ("NSCLC") harboring epidermal growth factor receptor exon 20 ("EGFRex20") insertion mutations who received zipalertinib after prior treatment with amivantamab. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report furnished pursuant to Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.

01 Other Events

Item 8.01 Other Events. On June 1, 2024, the Company announced initial clinical data from the pivotal Phase 2b portion of its REZILIENT1 clinical trial of zipalertinib in patients with NSCLC harboring EGFRex20 insertion mutations who received zipalertinib after prior treatment with amivantamab. As of a January 12, 2024 data cut-off, 31 patients had been enrolled. Patients had received a median of three prior systemic anti-cancer regimens, including prior platinum-based chemotherapy, prior anti-PD1/L1 therapy, and prior EGFR tyrosine kinase inhibitor therapy. At the data cut-off, 18 patients were evaluable for response and showed similar anti-tumor activity compared with those post prior chemotherapy in the previously reported Phase 1/2a part of the clinical trial, as shown below. Module C (post chemo and amivantamab +/- other exon 20 insertion treatment) (N=18) Phase 1/2a results (post chemo) 1 (N=39) Overall response rate (confirmed) 39% 41% Disease control rate 2 94% 97% Duration of response (months) NE NE Progression-free survival (months) NE 12 NE = not yet estimable 1 Piotrowska Z, et al. JCO 2023 2 Disease control rate = (complete response + partial response + stable disease)/response-evaluable The Company is co-developing zipalertinib with an affiliate of Taiho Pharmaceutical Co., Ltd through a suite of REZILIENT clinical trials, including two ongoing pivotal clinical trials in first line and second line exon20 insertion NSCLC as well as clinical trials in other patient populations, such as patients with active brain metastases and those with uncommon EGFR mutations. Both Module B2 (post chemotherapy only) and Module C (post approved exon20 insertion mutation treatments) of the pivotal REZILIENT1 clinical trial remain on track to complete enrollment

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Cullinan Therapeutics, Inc. on June 1, 2024, furnished herewith 99.2 Investor presentation 104 Cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CULLINAN THERAPEUTICS, INC. Date: June 3, 2024 By: /s/ Mary Kay Fenton Mary Kay Fenton Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.